News Category
Kairos Pharma's CEO will present at the H.C. Wainwright conference, highlighting its lead candidate ENV-105 designed to overcome cancer drug resistanc...
GeoVax applauds the new Gavi-funded global mpox vaccine stockpile as a step toward sustained preparedness, while highlighting its GEO-MVA candidate's ...
VERAXA Biotech (NASDAQ: VRXA) has named veteran financial executive Raju Willener as CFO, effective immediately, to support its capital strategy and a...
Onco-Innovations Ltd. advances its oncology pipeline with key milestones in manufacturing, IND-enabling activities, partnerships, and funding, positio...
OS Animal Health, a subsidiary of OS Therapies, showcased its innovative HER2-targeting immunotherapy for canine osteosarcoma at the Moody Capital Sol...
Quantum BioPharma's FDA clearance to test Lucid-MS in phase 2 trials marks a potential breakthrough in multiple sclerosis treatment by targeting myeli...
A new study from Washington University School of Medicine highlights the growing role of laser interstitial thermal therapy (LITT) in brain cancer tre...
Quantum BioPharma's Lucid-MS, a first-in-class drug candidate for multiple sclerosis, has received FDA clearance for Phase 2 trials, potentially marki...
NanoViricides has registered its Phase II clinical trial for NV-387 Oral Gummies as a treatment for Ebola in the Democratic Republic of Congo, marking...
Quantum BioPharma's Lucid-MS has received FDA clearance for a Phase 2 trial in MS, marking a step toward a targeted treatment for demyelination.
New federal data shows youth tobacco use at historic lows, while FDA's recent authorization of ZYN nicotine pouches offers adult smokers a scientifica...
A large study reveals that colorectal cancer patients who develop brain metastases have shorter survival, with timing significantly impacting prognosi...
Onco-Innovations reports significant progress in developing ONC010, a PNKP inhibitor for cancer therapy, including high-purity API production and plan...
VERAXA Biotech AG (NASDAQ: VRXA) has appointed Raju Willener as CFO to lead its capital strategy and support the development of its proprietary BiTAC(...
OS Therapies is set to engage with investors at the Moody Capital conference while approaching critical regulatory decisions and data readouts for its...
A preclinical study suggests that administering immunotherapy before tumor removal surgery could improve treatment outcomes for glioblastoma patients,...
New research from Mass General Brigham shows that unintended radiation exposure to the thymus during lung cancer treatment is associated with worse cl...
Salman Fazal, MD, a hematologist and transplant specialist at UPMC Hillman Cancer Center in Harrisburg, has been named a 2026 Castle Connolly Top Doct...
NanoViricides is progressing its measles treatment NV-387 to Phase II trials, leveraging FDA designations, as measles cases surge globally.
TransCode Therapeutics announced preclinical results showing its lead candidate TTX-MC138 improves survival in a breast cancer bone metastasis model, ...
A nurse's personal battle with metastatic triple-negative breast cancer underscores the importance of understanding new treatments like antibody-drug ...
In a Novartis-sponsored discussion, a prostate cancer patient and a Prostate Cancer Foundation expert highlight the importance of PSMA testing for gui...
Heidelberg Pharma and Huadong Medicine have received NMPA approval for a Phase Ib/II trial of HDP-101 in combination therapies for relapsed/refractory...
A new peer-reviewed study published in Critical Care Medicine shows that VolitionRx's Nu.Q NETs H3.1 biomarker independently predicts 28-day mortality...
Novogenia's U.S. launch of the MGT Plus methylation test expands genetic analysis to 27 genes across six pathways, potentially impacting personalized ...
Citius Pharmaceuticals is transitioning to a commercial-stage biopharma with FDA-approved LYMPHIR generating revenue, while advancing late-stage candi...
Annovis Bio announced a corporate update webinar for September 2, discussing its Phase 3 Alzheimer's trial, open-label studies, and regulatory milesto...
A new study suggests a personalized mRNA vaccine can prevent melanoma recurrence for years, offering hope for cancer treatment.
Creative Biolabs announces a webinar featuring Dr. Greg M. Delgoffe to discuss modeling T cell dysfunction in the tumor microenvironment, highlighting...
Dr. David Zelby, a Marietta prosthodontist with over 40 years of experience, has been named a 2026 Castle Connolly Top Dentist, an honor given to only...
A new T cell therapy could transform treatment for recurrent glioblastoma, a disease with few effective options, offering new hope for patients.
VERAXA Biotech and Secarna's early in vitro results show their AOC candidate is more potent than unconjugated oligonucleotides, supporting the approac...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate program into the next development stage after completing the initial OmniAb co...
The Keith Dagostino Scholarship for Cancer Survivors opens applications, offering financial aid to undergraduate cancer survivors across the U.S. to r...
VERAXA Biotech received favorable Scientific Advice from Germany's Paul-Ehrlich-Institute for its lead BiTAC-TCE cancer therapy, potentially reducing ...
VERAXA Biotech's proprietary BiTAC platform aims to improve cancer therapy precision, with lead programs advancing toward regulatory activities and a ...
Onco-Innovations has entered a non-binding LOI with Ifowonco Informatics to potentially acquire an exclusive option on a small-molecule LAG-3 inhibito...
A new study reveals that nearly 80% of young adults have early signs of cardiovascular-kidney-metabolic syndrome, linking advanced stages to arterial ...
Quantum BioPharma is advancing a novel MS treatment focusing on myelin protection, potentially addressing disease progression that current therapies m...
A mathematical study published in Mathematical Business proposes a solution to melanoma therapy resistance, potentially improving treatment outcomes f...
Quantum BioPharma's FDA-cleared phase 2 trial of Lucid-MS highlights a shift in MS treatment toward protecting the nervous system, addressing an unmet...
VERAXA Biotech's collaboration with Ardigen aims to use AI to identify optimal dual-target combinations for cancer therapies, potentially reducing dev...
Researchers have identified a protein on glioblastoma cells that could be targeted to make the cancer more vulnerable to existing treatments, potentia...
NanoViricides expects to begin a Phase II clinical trial of its oral antiviral NV-387 for Ebola in the DRC, potentially offering a more accessible tre...
The 20th Annual Sickle Cell Disease Educational Summit, hosted by Cayenne Wellness Center, will celebrate two decades of progress in treatment and adv...
Helix BioPharma Corp. has appointed Dr. Markus Loeffler as Chief Medical Officer to lead its clinical development programs, including the upcoming Pha...
The summit aims to address the unique challenges faced by Hispanic and Latino individuals with sickle cell disease through culturally relevant educati...
LCFA and IASLC fund two promising scientists with $200,000 each to advance research on lung microbiome's role in cancer and metabolic pathways in drug...
